구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | JCAR017 (JCAR017, JCAR017 (lisocabtagene maraleucel) 2-dose schedule, lisocabtagene maraleucel) Juno Therapeutics, a Subsidiary of…·Non-Hodgkin Lymphoma 34 trials |
|---|---|
Overview Program | JCAR017 (lisocabtagene maraleucel) 2-dose schedule |
Overview Company | Juno Therapeutics, a Subsidiary of Celgene |
Overview Modality | CGT |
Overview Target | Non-Hodgkin Lymphoma |
Overview Indication | Non-Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Mechanism | CAR T-cell patients is largely dependent on institutional experience |
MoA Biomarker | biomarker that predicts delayed humoral immune recovery, increased infectious events, and treatment-related m |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse |
Toxicology Major finding | Comparative outcomes of lisocabtagene maraleucel versus an external control arm in third-line or later relapsed or refractory follicular lymphoma.. In TRANSCEND FL, lisocabtagene maraleucel (liso-cel) demonstrated strong efficacy, with 97% overall response rate (ORR) and 94% complete response (CR) rate in third-line or later (3 L+) follicular lymphoma (FL). Here, we compared efficacy and sa… |
Toxicology CRS | Reported |
Clinical Safety signal | Comparative outcomes of lisocabtagene maraleucel versus an external control arm in third-line or later relapsed or refractory follicular lymphoma.. In TRANSCEND FL, lisocabtagene maraleucel (liso-cel) demonstrated strong efficacy, with 97% overall response rate (ORR) and 94% complete response (CR) rate in third-line or later (3 L+) follicular lymphoma (FL). Here, we compared efficacy and sa… |
Clinical Selected reported efficacy | ORR 80.5% |
Clinical Reported ORR | 53.7% |
Clinical Reported PFS | 5.86 |
Clinical Reported OS | 21.88 |
Clinical Result source | ClinicalTrials.gov NCT03744676 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT03744676 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | JCAR017 (JCAR017, JCAR017 (lisocabtagene maraleucel) 2-dose schedule, lisocabtagene maraleucel) Juno Therapeutics, a Subsidiary of…·Non-Hodgkin Lymphoma 34 trials |
|---|---|
Overview Program | JCAR017 (lisocabtagene maraleucel) 2-dose schedule |
Overview Company | Juno Therapeutics, a Subsidiary of Celgene |
Overview Modality | CGT |
Overview Target | Non-Hodgkin Lymphoma |
Overview Indication | Non-Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Mechanism | CAR T-cell patients is largely dependent on institutional experience |
MoA Biomarker | biomarker that predicts delayed humoral immune recovery, increased infectious events, and treatment-related m |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse |
Toxicology Major finding | Comparative outcomes of lisocabtagene maraleucel versus an external control arm in third-line or later relapsed or refractory follicular lymphoma.. In TRANSCEND FL, lisocabtagene maraleucel (liso-cel) demonstrated strong efficacy, with 97% overall response rate (ORR) and 94% complete response (CR) rate in third-line or later (3 L+) follicular lymphoma (FL). Here, we compared efficacy and sa… |
Toxicology CRS | Reported |
Clinical Safety signal | Comparative outcomes of lisocabtagene maraleucel versus an external control arm in third-line or later relapsed or refractory follicular lymphoma.. In TRANSCEND FL, lisocabtagene maraleucel (liso-cel) demonstrated strong efficacy, with 97% overall response rate (ORR) and 94% complete response (CR) rate in third-line or later (3 L+) follicular lymphoma (FL). Here, we compared efficacy and sa… |
Clinical Selected reported efficacy | ORR 80.5% |
Clinical Reported ORR | 53.7% |
Clinical Reported PFS | 5.86 |
Clinical Reported OS | 21.88 |
Clinical Result source | ClinicalTrials.gov NCT03744676 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT03744676 |
추천 비교
추천 비교